XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of common stock warrants

Common stock warrants

As of March 31, 2022, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following:

 

Issuance Date

 

Number of Shares of Common Stock Issuable

 

Exercise Price

 

Classification

 

Expiration Date

May 9, 2017

 

33,964

 

$

11.31

 

Equity

 

May 8, 2027

July 19, 2019

 

43,878

 

$

11.31

 

Equity

 

July 18, 2029

 

 

77,842

 

 

 

 

 

 

 

Schedule of Shares Reserved for Future Issuance

The Company has shares of common stock reserved for future issuances as follows:

 

 

 

March, 31

 

December, 31

 

 

2022

 

2021

Warrants to purchase common stock

 

77,842

 

77,842

Common stock options issued and outstanding

 

2,179,647

 

2,175,685

Common stock available for future grants

 

1,924,967

 

1,934,095

Restricted stock units issued and outstanding

 

390,750

 

394,750

Common stock available for ESPP

 

401,164

 

401,164

Schedule of Stock Option Activity

A summary of stock option activity is set forth below (in thousands, except share and per share data):

 

 

Number of
Shares
Underlying
Outstanding
Options

 

Weighted
Average
Exercise
Price

 

Weighted
Average
Remaining
Contractual
Term (in years)

 

 

Aggregate
Intrinsic
Value

Outstanding, January 1, 2022

2,175,685

 

$

9.27

 

8.68

 

$

2,856

Options granted

39,600

 

$

5.49

 

 

 

 

 

Options exercised

(5,166)

 

$

0.61

 

 

 

 

 

Options forfeited or cancelled

(30,472)

 

$

8.06

 

 

 

 

 

Outstanding, March 31, 2022

2,179,647

 

$

9.24

 

8.46

 

$

2,383

Shares exercisable March 31, 2022

1,542,586

 

$

9.30

 

8.17

 

$

1,830

Vested and expected to vest, March 31, 2022

2,179,647

 

$

9.24

 

8.46

 

$

2,383

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense recognized was as follows (in thousands):

 

 

Three Months Ended March 31,

 

2022

 

2021

Cost of goods sold

$

69

 

$

15

Sales and marketing

 

591

 

 

63

Research and development

 

14

 

 

1

General and administrative

 

849

 

 

52

Total

$

1,523

 

$

131

 

The above stock-based compensation expense related to the following equity-based awards (in thousands):

 

Three Months Ended March 31,

 

2022

 

2021

Stock options

$

1,026

 

$

131

RSU

 

497

 

 

  —

Total

$

1,523

 

$

131

Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions The fair value of stock options was estimated using the following weighted-average assumptions:

 

 

Three Months Ended March 31,

 

2022

 

2021

Expected volatility

70.8%

 

 

72.9% - 74.6%

Risk-free interest rate

1.9%

 

 

0.6% - 1.1%

Dividend yield

0%

 

 

0%

Expected term

6 years

 

 

5 - 6 years